NYSE - Delayed Quote USD

West Pharmaceutical Services, Inc. (WST)

Compare
293.02 -0.75 (-0.26%)
At close: August 8 at 4:00 PM EDT
295.50 +2.48 (+0.85%)
After hours: August 8 at 5:54 PM EDT
Loading Chart for WST
DELL
  • Previous Close 293.77
  • Open 297.89
  • Bid 260.00 x 800
  • Ask 292.18 x 900
  • Day's Range 291.27 - 299.40
  • 52 Week Range 265.00 - 415.73
  • Volume 657,985
  • Avg. Volume 665,785
  • Market Cap (intraday) 21.256B
  • Beta (5Y Monthly) 1.00
  • PE Ratio (TTM) 41.74
  • EPS (TTM) 7.02
  • Earnings Date Oct 24, 2024 - Oct 28, 2024
  • Forward Dividend & Yield 0.80 (0.27%)
  • Ex-Dividend Date Jul 31, 2024
  • 1y Target Est 353.18

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

www.westpharma.com

10,600

Full Time Employees

December 31

Fiscal Year Ends

Recent News: WST

View More

Performance Overview: WST

Trailing total returns as of 8/8/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

WST
16.64%
S&P 500
11.52%

1-Year Return

WST
22.44%
S&P 500
17.72%

3-Year Return

WST
30.98%
S&P 500
19.90%

5-Year Return

WST
112.52%
S&P 500
84.44%

Compare To: WST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: WST

View More

Valuation Measures

Annual
As of 8/7/2024
  • Market Cap

    21.31B

  • Enterprise Value

    21.18B

  • Trailing P/E

    41.79

  • Forward P/E

    43.67

  • PEG Ratio (5yr expected)

    5.70

  • Price/Sales (ttm)

    7.61

  • Price/Book (mrq)

    8.27

  • Enterprise Value/Revenue

    7.36

  • Enterprise Value/EBITDA

    27.69

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    18.25%

  • Return on Assets (ttm)

    10.66%

  • Return on Equity (ttm)

    19.72%

  • Revenue (ttm)

    2.88B

  • Net Income Avi to Common (ttm)

    524.9M

  • Diluted EPS (ttm)

    7.02

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    446.2M

  • Total Debt/Equity (mrq)

    12.19%

  • Levered Free Cash Flow (ttm)

    172.09M

Research Analysis: WST

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

265.00
353.18 Average
293.02 Current
470.00 High
 

Company Insights: WST

Research Reports: WST

View More
  • Raising target price to $320.00

    WEST PHARMACEUTICAL SERVICES has an Investment Rating of HOLD; a target price of $320.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • Lowering target price to $314.00

    WEST PHARMACEUTICAL SERVICES has an Investment Rating of HOLD; a target price of $314.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • West Pharmaceutical Earnings: Disappointing Performance; Guidance Revised Down; Shares Undervalued

    West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

    Rating
    Price Target
     
  • West Earnings: First-Quarter Revenue Slightly Better Than Expected; Maintaining Our Fair Value

    West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

    Rating
    Price Target
     

People Also Watch